¼¼°èÀÇ °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ½ÃÀå Á¶»ç º¸°í¼ - »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)
Global Hyperpigmentation Disorder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
»óǰÄÚµå
:
1288830
¸®¼Ä¡»ç
:
Value Market Research
¹ßÇàÀÏ
:
2023³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 189 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
°ú´Ù»ö¼ÒÄ§Âø Ä¡·á ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023-2030³â Á¶»ç ±â°£ µ¿¾È CAGR 9.21%·Î 2022³â 580¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â °ÅÀÇ 1,173¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
°ú´Ù»ö¼ÒÄ§Âø Ä¡·á´Â ÇǺÎÀÇ °í¹ÎÀÎ »ö¼ÒÄ§ÂøÀ» Ä¡·áÇϱâ À§ÇÑ ½Ã¼úÀÔ´Ï´Ù. »ö¼ÒÄ§ÂøÀº ÁÖº¯ ÇÇºÎ¿Í ºñ±³ÇÏ¿© °ËÀº »öÀ¸·Î º¯ÇÑ ÇǺΠ¹ÝÁ¡À» ¸»Çϸç ÀϹÝÀûÀ¸·Î ¾ó·è´ú·èÇϰųª °í¸£Áö ¾ÊÀº ¿Ü°üÀ» ÃÊ·¡ÇÕ´Ï´Ù. »ö¼Ò Ä§ÂøÀº ÇǺθ¦ °Ë°Ô ¸¸µå´Â »ö¼ÒÀÎ ¸á¶ó´Ñ ¼¼Æ÷°¡ ÇǺÎÀÇ ±íÀº Ãþ¿¡¼ ¸á¶ó´ÑÀ» »ý¼ºÇÏ¿© ¹ß»ýÇÕ´Ï´Ù. ¸á¶ó´ÑÀÌ °úµµÇÏ°Ô »ý¼ºµÇ¸é ÇǺο¡ °ËÀº ¹ÝÁ¡ÀÌ »ý±æ ¼ö ÀÖ½À´Ï´Ù. ¸á¶ó´Ñ ÇÕ¼ºÀÌ °¨¼ÒÇϸé ÇǺΠ»ö¼Ò Ä§ÂøÀÌ ¹ß»ýÇÕ´Ï´Ù. »ö¼Ò Ä§ÂøÀ» Ä¡·áÇϱâ À§ÇØ ÈÀåǰ, ·¹ÀÌÀú Ä¡·á, ÈÇÐÀû ¹ÚÇǼú µîÀÌ »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ:
÷´Ü ±â¼ú ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ È®´ë´Â °ú´Ù»ö¼ÒÄ§Âø Ä¡·áÀÇ ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ö¼Ò Ä§Âø°ú °ü·ÃµÈ »çȸÀû ³«ÀÎÀÌ °¨¼ÒÇÏ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. »ö¼Ò Ä§Âø °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡, ÇǺΠȸÃá ¹× Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °ú´Ù»ö¼ÒÄ§Âø Ä¡·á °ü·Ã ±â¾÷µéÀº ÈÀåǰ ±â¼ú ¹ßÀü°ú ÀÌ¿¡ µû¸¥ ÇǺΠ°ü¸®¿¡¼ ÈÀåǰ »ç¿ë Áõ°¡·Î °æÁ¦Àû ÀÌÀÍÀ» ¾ò°í ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ½ÃÀåÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ½ÃÀåÀ» È®´ëÇÏ´Â µ¥ µµ¿òÀ̵Ǵ Çõ½ÅÀûÀÌ°í »õ·Î¿î ¼Ö·ç¼ÇÀ» °³¹ßÇϱâ À§ÇØ ³ª³ë ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ °ÈÇϰí ÀÖ½À´Ï´Ù.
ÀÌ Á¶»ç º¸°í¼´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ¼¼°è ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. °ú´Ù»ö¼ÒÄ§Âø Ä¡·á »ê¾÷ÀÇ ¼ºÀå°ú Ãß¼¼´Â º» ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
Áö¿ªº° ºÐ¼®:
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
ÀÌ Á¶»ç º¸°í¼´Â ¶ÇÇÑ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÇʰú ¼¼°è °æÀï »óȲ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ °ßÇØ¸¦ ´Ù·ç°í ÀÖ½À´Ï´Ù. °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Aerolase Corporation, Candela Corporation, Cynosure, Galderma S.A., iSCLINICAL, ISDIN, L'Oreal(SkinCeuticals, SkinCeuticals, La Roche-Posay), LumenisBeauty, Inc. Skinbetterscience &La Roche-Posay), LumenisBe Ltd., Mesoestetics, Obagi Cosmeceuticals LLC, PCA Skin, Scientis, Sente, SkinMedica(AbbVie), SoltaMedical, ZO SkinMedica, ZO SkinMedica, ZO SkinMedica, ZO SkinMedica, ZO SkinMedica SoltaMedical, ZO Skin Health Inc. µîÀÔ´Ï´Ù. ÀÌ ¼½¼ÇÀº ÁÖ¿ä M&A, ¹Ì·¡ ¿ª·®, ÆÄÆ®³Ê½Ê, À繫 °³¿ä, Çù¾÷, ½ÅÁ¦Ç° °³¹ß, ½ÅÁ¦Ç° Ãâ½Ã µî ´Ù¾çÇÑ Àü·«Àû ¹ßÀüÀ» Æ÷ÇÔÇÑ °æÀï ȯ°æÀÇ Àü¹ÝÀûÀÎ °³¿ä·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.
¸ÂÃãÇü ¿ä±¸ »çÇ×ÀÌ ÀÖ´Â °æ¿ì ´ç»ç¿¡ ¹®ÀÇÇϽʽÿÀ. ¿ì¸®ÀÇ Á¶»ç ÆÀÀº ±ÍÇÏÀÇ Çʿ信 µû¶ó ¸ÂÃãÇü º¸°í¼¸¦ Á¦°ø ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
- º» º¸°í¼ÀÇ ³»¿ë
- Á¶»ç ¹üÀ§
- Á¶»ç ¹æ¹ý
- ½ÃÀå Á¶»ç °úÁ¤
- ½ÃÀå Á¶»ç ¹æ¹ý
Á¦2Àå ÁÖ¿ä ¿ä¾à
- ½ÃÀå ÇÏÀ̶óÀÌÆ®
- ¼¼°è ½ÃÀå ÇöȲ
Á¦3Àå °ú´Ù»ö¼ÒÄ§Âø Ä¡·á - »ê¾÷ ºÐ¼®
- ¼·Ð - ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ½ÃÀå ±âȸ
- »ê¾÷ µ¿Çâ
- Porter's Five Forces ºÐ¼®
- ½ÃÀå ¸Å·Â ºÐ¼®
Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®
- ¹ë·ùüÀÎ ºÐ¼®
- ¿øÀç·á ºÐ¼®
- ¿øÀç·á ¸®½ºÆ®
- ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
- ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
- ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
- ¸¶ÄÉÆÃ Ã¤³Î
- Á÷Á¢ ¸¶ÄÉÆÃ
- °£Á¢ ¸¶ÄÉÆÃ
- ¸¶ÄÉÆÃ Ã¤³Î µ¿Çâ
Á¦5Àå COVID-19ÀÇ ¹ß»ý¿¡ ÀÇÇÑ ¿µÇ⠺м®
Á¦6Àå °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ¼¼°è ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°
- Ä¡·á À¯Çüº° °³¿ä
- ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
- Ä¡·á À¯Çüº° ºÐ¼®
- ÄÚ½º¸Þ½´Æ¼ÄÃ
- ·¹ÀÌÀú Ä¡·á
- ÄɹÌÄà Çʸµ
- ¹Ì¼¼¹ÚÇÇ
- ±¤Ä¡·á
- ±âŸ
Á¦7Àå °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ¼¼°è ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°
- Áúȯ ÀûÀÀº° °³¿ä
- ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
- ÀûÀÀÁõº° ºÐ¼®
- ±â¹Ì
- ¿°Áõ ÈÄ »ö¼ÒÄ§Âø
- Àϱ¤ ÈæÀÚ
- ±âŸ
Á¦8Àå °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ¼¼°è ½ÃÀå ÆÇ¸Å ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
- ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
- ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
- ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®
- º´¿ø
- ¿¡½ºÅׯ½ »ì·Õ¡¤ÇǺΰú Ŭ¸®´Ð
- ±âŸ
Á¦9Àå °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ¼¼°è ½ÃÀå ÆÇ¸Å ºÐ¼® : Áö¿ªº°
- Áö¿ªº° ÆÇ¸Å ºÐ¼®
- ¼·Ð ÆÇ¸Å ºÐ¼®
- ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ
- ºÏ¹Ì : ºÎ¹®º°
- ºÏ¹Ì : ±¹°¡º°
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ
- À¯·´ : ºÎ¹®º°
- À¯·´ : ±¹°¡º°
- ¿µ±¹
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- È£ÁÖ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ
- ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
- ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Æä·ç
- Ä¥·¹
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
- »ç¿ìµð¾Æ¶óºñ¾Æ
- UAE
- À̽º¶ó¿¤
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ±â¾÷ °æÀï »óȲ
- °ú´Ù»ö¼ÒÄ§Âø Ä¡·á ½ÃÀå °æÀï
- Á¦ÈÞ¡¤Çù¾÷¡¤ÇÕÀÇ
- ÀμöÇÕº´
- ½ÅÁ¦Ç° ¹ß¸Å
- ±âŸ °³¹ß
Á¦11Àå ±â¾÷ °³¿ä
- ÁÖ¿ä 10°³»ç Á¡À¯À² ºÐ¼®
- ½ÃÀå ÁýÁßµµ
- Aerolase Corporation
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- Candela Corporation
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- Cynosure
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- Galderma S.A.
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- iSCLINICAL
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- ISDIN
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- L'Oreal(SkinCeuticals Skinbetterscience & La Roche-Posay)
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- LumenisBe Ltd.
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- Mesoestetics
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- Obagi Cosmeceuticals LLC
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- PCA Skin
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- Scientis
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- Sente
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- SkinMedica(AbbVie)
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- SoltaMedical
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ °³¹ß »óȲ
- ZO Skin Health Inc.
- ±â¾÷ °³¿ä
- ±â¾÷ ¸ÅÃâ
- Á¦Ç° Á¤º¸
- ÃÖ±ÙÀÇ µ¿Çâ
Âü°í : ±â¾÷ °³¿ä Áß¿¡¼ À繫 »ó¼¼³ª ÃÖ±ÙÀÇ °³¹ß¿¡ ´ëÇØ¼´Â ÀÔ¼ö °¡´ÉÇÑ Á¤º¸¸¦ ±â¹ÝÀ¸·Î Çϸç, ºñ°ø°³ ±â¾÷ÀÇ °æ¿ì Àû¿ëµÇÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.
ksm
¿µ¹® ¸ñÂ÷
The global demand for Hyperpigmentation Disorder Treatment Market is presumed to reach the market size of nearly USD 11.73 MN by 2030 from USD 5.8 MN in 2022 with a CAGR of 9.21% under the study period 2023 - 2030.
Hyperpigmentation disorder treatments are procedures to treat hyperpigmentation which is a skin-related concern. Pigmentation refers to patches on the darkened skin compared to the surrounding skin, typically resulting in a patchy or uneven look. Hyperpigmentation occurs when melanocytes, a skin-darkening pigment, generate melanin in the deep skin layers. An overproduction of melanin can cause dark patches of skin. A reduction in melanin synthesis results in skin hypopigmentation. Cosmeceuticals, laser therapy, and chemical peels can all be used to treat hyperpigmentation issues.
Market Dynamics:
Increasing investments in research and development for cutting-edge technology may encourage market expansion for hyperpigmentation disorder treatments. The diminishing of social stigma associated with pigmentation may also aid market growth. The increased prevalence of hyperpigmentation-related disorders and increased awareness of skin rejuvenation and treatment alternatives are projected to boost the hyperpigmentation disorder treatment market. Companies involved in treating hyperpigmentation disorders are benefiting financially from cosmeceutical technological improvements and the resulting rise in cosmeceutical usage in skincare hence, expanding the hyperpigmentation disorder treatment market. Key players are boosting their investments in nanotechnology to develop innovative and new solutions that will help to broaden the hyperpigmentation disorder treatment market.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of hyperpigmentation disorder treatment. The growth and trends of hyperpigmentation disorder treatment industry provide a holistic approach to this study.
Market Segmentation:
This section of the hyperpigmentation disorder treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Treatment Type
- Cosmeceuticals
- Laser Therapy
- Chemical Peels
- Microdermabrasion
- Phototherapy
- Others
By Disease Indication
- Melasma
- Post-Inflammatory Hyperpigmentation
- Solar Lentigines
- Others
By End-User
- Hospitals
- Esthetic Clinics & Dermatology Centers
- Others
Regional Analysis:
This section covers the regional outlook, which accentuates current and future demand for the Hyperpigmentation Disorder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the hyperpigmentation disorder treatment market include Aerolase Corporation, Candela Corporation, Cynosure, Galderma S.A., iSCLINICAL, ISDIN, L'Oreal (SkinCeuticals, Skinbetterscience & La Roche-Posay), LumenisBe Ltd., Mesoestetics, Obagi Cosmeceuticals LLC, PCA Skin, Scientis, Sente, SkinMedica (AbbVie), SoltaMedical, ZO Skin Health Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . HYPERPIGMENTATION DISORDER TREATMENT - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Type
- 3.7.2 Market Attractiveness Analysis By Disease Indication
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
6 . GLOBAL HYPERPIGMENTATION DISORDER TREATMENT MARKET ANALYSIS BY TREATMENT TYPE
- 6.1 Overview by Treatment Type
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Treatment Type
- 6.4 Cosmeceuticals Historic and Forecast Sales by Regions
- 6.5 Laser Therapy Historic and Forecast Sales by Regions
- 6.6 Chemical Peels Historic and Forecast Sales by Regions
- 6.7 Microdermabrasion Historic and Forecast Sales by Regions
- 6.8 Phototherapy Historic and Forecast Sales by Regions
- 6.9 Others Historic and Forecast Sales by Regions
7 . GLOBAL HYPERPIGMENTATION DISORDER TREATMENT MARKET ANALYSIS BY DISEASE INDICATION
- 7.1 Overview by Disease Indication
- 7.2 Historical and Forecast Data
- 7.3 Analysis by Disease Indication
- 7.4 Melasma Historic and Forecast Sales by Regions
- 7.5 Post-inflammatory Hyperpigmentation Historic and Forecast Sales by Regions
- 7.6 Solar Lentigines Historic and Forecast Sales by Regions
- 7.7 Others Historic and Forecast Sales by Regions
8 . GLOBAL HYPERPIGMENTATION DISORDER TREATMENT MARKET SALES ANALYSIS BY END-USER
- 8.1 Overview by End-user
- 8.2 Historical and Forecast Data
- 8.3 Analysis by End-user
- 8.4 Hospitals Historic and Forecast Sales by Regions
- 8.5 Esthetic Clinics & Dermatology Centers Historic and Forecast Sales by Regions
- 8.6 Others Historic and Forecast Sales by Regions
9 . GLOBAL HYPERPIGMENTATION DISORDER TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY
- 9.1. Regional Outlook Sales Analysis
- 9.2. Introduction Sales Analysis
- 9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
- 9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
- 9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
- 9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
- 9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis
10 . COMPETITIVE LANDSCAPE OF THE HYPERPIGMENTATION DISORDER TREATMENT COMPANIES
- 10.1. Hyperpigmentation Disorder Treatment Market Competition
- 10.2. Partnership/Collaboration/Agreement
- 10.3. Merger And Acquisitions
- 10.4. New Product Launch
- 10.5. Other Developments
11 . COMPANY PROFILES OF HYPERPIGMENTATION DISORDER TREATMENT INDUSTRY
- 11.1. Top 10 Company Share Analysis
- 11.2. Market Concentration Rate
- 11.3. Aerolase Corporation
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
- 11.4. Candela Corporation
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
- 11.5. Cynosure
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
- 11.6. Galderma S.A.
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
- 11.7. iSCLINICAL
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
- 11.8. ISDIN
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
- 11.9. L'Oreal (SkinCeuticals Skinbetterscience & La Roche-Posay)
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
- 11.10. LumenisBe Ltd.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
- 11.11. Mesoestetics
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
- 11.12. Obagi Cosmeceuticals LLC
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
- 11.13. PCA Skin
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments
- 11.14. Scientis
- 11.14.1. Company Overview
- 11.14.2. Company Revenue
- 11.14.3. Products
- 11.14.4. Recent Developments
- 11.15. Sente
- 11.15.1. Company Overview
- 11.15.2. Company Revenue
- 11.15.3. Products
- 11.15.4. Recent Developments
- 11.16. SkinMedica (AbbVie)
- 11.16.1. Company Overview
- 11.16.2. Company Revenue
- 11.16.3. Products
- 11.16.4. Recent Developments
- 11.17. SoltaMedical
- 11.17.1. Company Overview
- 11.17.2. Company Revenue
- 11.17.3. Products
- 11.17.4. Recent Developments
- 11.18. ZO Skin Health Inc.
- 11.18.1. Company Overview
- 11.18.2. Company Revenue
- 11.18.3. Products
- 11.18.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
°ü·ÃÀÚ·á